logo-loader
viewParallax Health Sciences Inc.

Parallax executes international medical supply chain agreement for coronavirus testing kits, personal protective equipment

SAGICO USA and Parallax Diagnostics have combined forces to provide reliable product procurement from international manufacturers

Parallax Health Sciences Inc. - Parallax executes international medical supply chain agreement for COVID-19 testing kits, personal protective equipment
Parallax said that 'world-leading' inventories and end-to-end logistics services related to the coronavirus response are now available on the company's website

Parallax Health Sciences Inc (OTCMKTS:PRLX) said Monday that its subsidiary, Parallax Diagnostics Inc, has executed a joint venture supply chain agreement with the United States Marine Corps veteran-owned medical device company SAGICO USA for coronavirus (COVID-19) and personal protection equipment (PPE), from FDA-registered manufacturers.

SAGICO USA has a long track-record for getting US Food and Drug Administration (FDA) clearances, and other regulatory approvals for the distribution of medical products to government hospitals globally.

In a statement, the company said SAGICO USA and Parallax Diagnostics have “combined forces” to provide “reliable product procurement directly from international manufacturers” building on its established global manufacturing and diagnostics relationships stemming from its patented intellectual property.

“World leading inventories and end-to-end logistics services related to COVID-19 response are now available on our website,” the company noted.

Parallax said it is offering procurement managers — from both private and government entities — the ability to purchase much-needed PPE items from FDA-registered manufacturers. Items included on the Parallax online portal include “medical masks, invasive and passive ventilators, thermometers, medical protective gowns, face protection, other personal protective equipment and COVID-19 point of care test kits.” The PPE items are also available for export to any country, said the company.

READ: Parallax moves one step closer to a finished coronavirus test by securing antigens and anitbodies to use as markers

Nathaniel Bradley, who is the chief technology officer with Parallax Health Sciences, said the global response to the coronavirus pandemic has placed all three Parallax business pillars under “greater demand.”

“Our new relationship with Sagico USA will be instrumental in fortifying our operations and identifying the sustainable footholds in the market where we are focusing our efforts,” he added.

Most significantly, a coronavirus test is being developed on Parallax’s FDA-cleared and patented Target Diagnostics Test Platform, and the company believes it could be ready for the public by summer. 

The company operates three subsidiaries: Parallax Behavioral Health handles the patient-monitoring platform; Parallax Diagnostics oversees diagnostics delivery with an FDA-cleared analyzer and 25 FDA-cleared blood and urine tests; Parallax Health Management provides outcomes-optimization software to promote behavior modification.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Quick facts: Parallax Health Sciences Inc.

Price: 0.02 USD

OTCQB:PRLX
Market: OTCQB
Market Cap: $5.41 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Parallax Health Sciences Inc. named herein, including the promotion by the Company of Parallax Health Sciences Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Parallax Health Sciences on an 'accelerated path' in its...

Parallax Health Sciences Inc (OTCMKTS:PRLX) Chief Technology Office Nathaniel Bradley tells Proactive its subsidiary Parallax Diagnostics Inc is distributing vitamin D supplements to coronavirus medical and clinical services workers through a partnership with CURE Pharmaceutical Holding...

on 04/07/2020

2 min read